A nonneutralizing anti-HIV type 1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV type 1-susceptible cells. II. Inhibition of HIV type 1 captured and transferred by DC-SIGN

AIDS Research and Human Retroviruses

Volumn 22, Issue 9, 2006, Pages 874-883

  Lee, Seung Jae ^a   Arora, Reetakshi ^b   Bull, Lara M ^c   Arduino, Roberto C ^c   Garza, Laura ^a   Allan, Jonathan ^a   Kimata, Jason T ^b   Zhou, Paul ^a,d  

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIBODY FORMATION; CELL ADHESION MOLECULES; CELL CULTURE TECHNIQUES; CELL LINE; DENDRITIC CELLS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LECTINS, C-TYPE; MONOCYTES; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, CELL SURFACE; VIRUS REPLICATION;

EID: 33751052510     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.874     Document Type: Article

References (35)

1. Rossi M and Young JW: Human dendritic cells: Potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005;175:1373-1381.
2. Geijtenbeek TB, van Vliet SJ, Engering A, 't Hart BA, and van Kooyk Y: Self- and nonself-recognition by C-type lectins on dendritic cells. Annu Rev Immunol 2004;22:33-54.
3. Geijtenbeek TB and van Kooyk Y: Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity. APMIS 2003;111:698-714.
4. Geijterbeek TB, Torensma T, Van Vliet SJ, Van Dujinhoven GC, Adema GJ, and Van Kooyk Y: Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 2000;100:575-585.
5. Geijtenbeek TB, Krooshoop DJEB, Bleijs CA, van Vliet SJ, Duijnhoven GCF, Grabovsky V, Alon R, Figdor CG, and van Kooyk Y: DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 2000;1:353-357.
6. Geijterbeek TB, Kwon DS, Torensma R, Van Vliet SJ, Dujinhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, and van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhance trans-infection of T cells. Cell 2000;100:587-597.
7. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, and Hope TJ: Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003;300:1295-1297.
8. Pope M and Haase AH: Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003;9:847-849.
9. Takeda SN, Dorfman NA, Robert-Guroff M, Notkins AL, and Rando RF: Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domain in Escherichia coli. Hybridoma 1995;14:9-18.
10. Zhou P, Goldstein S, Devadas K, Tewari D, and Notkins AL: Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: Targeting the endoplasmic reticulum and trans-Golgi network. J Immunol 1998;160:1489-1496.
11. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
12. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, and Katinger H: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
13. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglamer R, Steindl F, and Katinger H: A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17:1757-1765.
14. Zwick MB., Labrjin AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Steigler G, Katinger H, Burton DR, and Parren PW: Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-10905.
15. Wyatt R and Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 1998;280:1884-1888.
16. Baldwin CE, Sanders RW, and Berkhout B: Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem 2003;10:1633-1642.
17. Lee S-J, Garza L, Yao J, Notkins V, and Zhou P: A non-neutralizing anti-HIV-1 antibody turns into a neutralizing antibody when expressed on the surface of HIV-1-susceptible cells: A new way to fight HIV. J Immunol 2004;173:4618-4626.
18. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, and Ho DD: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120 and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995;69:101-109.
19. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L, and the NIH/NIAID/DAIDS/ACTG Virology Laboratories: Standardization of sensitive human immunodeificiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-1794.
20. Mornor A, Bjorndal A, KewalRamani V, Littman DR, Inoue R, Thorstensson R, Fenyo EM, and Bjorling E: Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999;73:2343-2349.
21. Ndung'u T, Renjifo B, and Essex M: Construction and analysis of an infectious human immunodeficiency virus subtype C molecular clone. J Virol 2001;75:4964-4972.
22. Adachi A, Gendalman HE, Koenig S, Folks T, Willey R, Rasbon A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
23. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, and Hahn BH: Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication competent and defective viral genomes. J Virol 1991;65:3973-3985.
24. Wu L, Martin TD, Carrington M, and KewalRamani VN: Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. Virology 2004;318:17-23.
25. Zhou P, Lee JH, Moore P, and Brasky KM: High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32°C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. Hum Gene Ther 2001;12:1843-1855.
26. Kotani H, Newton PB III, Zhang S, Chiang YL, Otto E, Weayer L, Blease RM, Anderson WF, and McGarrity GJ: Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994;5:19-28.
27. cdc2 activity. J Virol 1995;69:6705-6711.
28. Freed EO, Myers DJ, and Risser R: Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope protein precursor gp160. J Virol 1989;63:4670-4675.
29. Overbaugh J, Anderson RJ, Ndinya-Achola JO, and Kreiss JK: Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses 1996;12:107-115.
30. Yu Kimata MT, Cella M, Biggins JE, White R, Hicks S, Wilson JM, Patel PG, Allan JS, Colonna M, and Kimata JT: Capture and transfer of simian immunodeficiency virus by macaque dendritic cells is enhanced by DC-SIGN. J Virol 2002;76:11827-11836.
31. Feinberg H, Mitchell DA, Drickamer K, and Weis WI: Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 2001;294:2163-2166.
32. Nobile C, Petit C, Moris A, Skrabel K, Abestado JP, Mammano F, and Schwartz O: Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long term transmission to lymphocytes. J Virol 2005;79:5386-5399.
33. Gould SJ, Booth AM, and Hildreth JEK: The Trojan exosome hypothesis. Proc Natl Acad Sci USA 2003;100:10592-10597.
34. Frankel SS, Steinman RM, Michael NL, Kim SR, Bhardwaj N, Pope M, Louder MK, Ehrenberg PK, Parren PWHI, Burton DR, Katinger H, VanCott TC, Robb ML, Birx DL, and Mascola JR: Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. J Virol 1998;72:9788-9794.
35. Ganesh L, Leung K, Lore K, Levin R, Panet A, Schwartz O, Koup RA, and Nabel GJ: Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies. J Virol 2004;78:11980-11987.